The Impact of Sarcopenia on COPD Exacerbation Admission Outcome and Further Exacerbation Risk

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

43 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-01-31

Study Completion Date

2020-06-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Chronic obstructive pulmonary disease (COPD) is more prevalent and has more impact on health status because of progressive air pollution, tobacco smoking and aging society. The COPD prevalence investigation in 2013 by phone call showed at least 6% of the population with more than 40 years-old in Taiwan. It also was the 7th ranking of death causes in Taiwan then. Apart from chronic inflammation in lung and deteriorated lung function, it had extrapulmonary complications, such as cardiovascular problems, osteoporosis and muscle wasting. The concept of sarcopenia was proposed at first in 1989. It increases the risk of falls, disability and lowering life quality. Besides, it increased the mortality risk after admission from acute ward. Thereafter, sarcopenia is one of COPD co-morbidities, which should have great impacts of COPD. The studies showed sarcopenia reduced exercise capacities and worsening dyspnea scores. On the other hand, COPD exacerbation brings significant health burden. But there is limited data about the effect on sarcopenia on COPD exacerbation. We conducted a prospective observational study. We measured skeletal muscle mass and the strength of the used hand grip within 3 days of admission and before discharge. Mortality and exacerbation in one year are the primary end-points

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Sarcopenia in Chronic Lung Diseases

NCT06280443

Sarcopenia COPD Asthma +1 more

RECRUITING

Feasibility of Proteomics in Chronic Lung Disease With Sarcopenia

NCT06312774

Sarcopenia Chronic Lung Disease

NOT_YET_RECRUITING

Chronic Obstructive Pulmonary Disease (COPD) Maintenance Treatment Patterns in China

NCT04853238

Pulmonary Disease, Chronic Obstructive

COMPLETED

The Anti-oxidant Effects of N-Acetylcysteine in Chronic Obstructive Pulmonary Disease (COPD)

NCT03956888

Chronic Obstructive Pulmonary Disease

COMPLETED PHASE3

Investigation of Chronic Obstructive Pulmonary Disease (COPD) Phenotypes and Endotypes in China

NCT04853225

Pulmonary Disease, Chronic Obstructive

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sarcopenia COPD Exacerbation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

COPD exacerbation

sarcopenia measurement

Intervention Type DIAGNOSTIC_TEST

BIA for fat free muscle mass hand grasp strength

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

sarcopenia measurement

BIA for fat free muscle mass hand grasp strength

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

COPD exacerbation criteria:

1. acute worsening respiratory symptoms without any other causes, And
2. Smoking more than 15 pack-years or the history of noxious gas exposure, And
3. Spirometry reports suggests obstructive ventilatory defect (FEV1/FVC \<0.7) or
4. Attending physicians diagnose as COPD by clinical parameters if spirometry data are not available while enrolling.

Definite COPD exacerbation: fulfill 1、2、3 Probable COPD exacerbation: fulfill 1、2、4

Exclusion Criteria

1. Significant fluid retention such as edema, pleural effusion or ascites,
2. Patients with permanent pacemaker or implantable cardioverter defibrillator ,
3. Morbid obesity with BMI \>34

Minimum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No